biostudies-literatureUnknown49(2)Marrano NUniversità degli Studi di Bari Aldo Moro<h4>Purpose</h4>First-line treatment for renal cell carcinoma (RCC) commonly includes immune checkpoint inhibitors (ICIs), either as monotherapy or in combination with anti-angiogenic agents. These therapies can lead to endocrine immune-related adverse events (irAEs). This study aimed to identify predictive risk factors for the development of endocrine irAEs associated with ICI-based therapies.<h4>Methods</h4>We conducted an observational, retrospective, single-center study involving 72 patients with RCC who initiated first-line treatment with ICIs (either in combination with another ICI or an anti-angiogenic agent) between January 2018 and May 2023. All patients had at least 18 months of clinical and biochemical follow-up.<h4>Results</h4>51.39% of patients experienced endocrine irAEs, incJournal of endocrinological investigation399-412https://www.ebi.ac.uk/biostudies/studies/S-EPMC12924852biostudies-literatureRisk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors.PMC12924852Perrini SGanini CCaporusso MCignarelli ALaviola LGiorgino FPorta CMarrano NNatalicchio ABorraccino AfalseRisk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors.<h4>Purpose</h4>First-line treatment for renal cell carcinoma (RCC) commonly includes immune checkpoint inhibitors (ICIs), either as monotherapy or in combination with anti-angiogenic agents. These therapies can lead to endocrine immune-related adverse events (irAEs). This study aimed to identify predictive risk factors for the development of endocrine irAEs associated with ICI-based therapies.<h4>Methods</h4>We conducted an observational, retrospective, single-center study involving 72 patients with RCC who initiated first-line treatment with ICIs (either in combination with another ICI or an anti-angiogenic agent) between January 2018 and May 2023. All patients had at least 18 months of clinical and biochemical follow-up.<h4>Results</h4>51.39% of patients experienced endocrine irAEs, inc2026-01-01T00:00:00Z2026 Feb2026-07-16T15:09:08.47Z2026-07-09T11:02:59.569ZS-EPMC129248524121241110.1007/s40618-025-02732-z